Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Trial Results
Biotech
Vertex drops asset in acute pain after phase 2 fail
All three dose levels of Nav1.8 inhibitor VX-993 failed to improve pain intensity over a 48-hour period compared to placebo.
Darren Incorvaia
Aug 4, 2025 5:34pm
Instil's licensed PD-L1xVEGF bispecific shows promise in China
Jul 31, 2025 2:10pm
Apnimed's sleep apnea star goes 2 for 2 in phase 3
Jul 23, 2025 6:00am
Okyo's eye drops reduce neuropathic eye pain in phase 2 win
Jul 16, 2025 11:57am
J&J lymphoma CAR-T hits 100% ORR in 10 patients
Jun 13, 2025 1:22pm
Former Pfizer antibody reduces cardio risk marker in ph. 2
May 20, 2025 7:30am
